The study is carried out in order to investigate if \[11C\]AZD2995, compared to \[11C\]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
13
Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
Single dose of i.v solution. Once for AD patients respective healthy volunteers.
Research Site
Stockholm, Sweden
Positron emission tomography using the radioligand (11C)AZD2995 or (11C)AZD2184
Time frame: Radioligand (11C)AZD2995.1-2 PET examinations for AD patients and 1 PET examination for healthy volunteers. - Radioligand (11C) AZD2184.One PET for AD patients respective healthy volunteers.
To assess safety and tolerability of [11C]AZD2995, [11C]AZD2184 and the study procedures, by assessment of adverse events, vital signs and laboratory variables.
Time frame: 3-4 visits with tests for the AD patients. 3 visits with tests for the healthy volunteers. All tests are not done at every visit.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.